BioWorld - Friday, June 5, 2020

Infection
%{topic} RSS Feed RSS

Gilead investor sentiment remains flat amid continued focus on next steps

February 5, 2020
By Michael Fitzhugh
No Comments
Modest revenue growth and a 2020 outlook that left analysts uninspired about its near-term prospects pushed Gilead Sciences Inc. shares (NASDAQ:GILD) down about 2% to close Feb. 5 at $65.87, despite growing sales of its HIV medicine, Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide), and what CEO Daniel O'Day called "a sense of urgency" around further business development.
Read More
2-5-Lumos-Febridx.png

Lumos Diagnostics scoops up $15M in series A to back Febridx test

February 5, 2020
By Liz Hollis
No Comments
With an eye toward expanding the reach of its Febridx rapid point-of-care (POC) test, Lumos Diagnostics has seen the closing of a $15 million series A round from Australia’s Planet Innovation. The funds will back a U.S. FDA pivotal clinical trial, as well as additional development and manufacturing resources for the company’s expanding full-service POC business.
Read More
Coronavirus microscopic model
Ebola, malaria, HIV, TCM

Researchers cast wide net for rapid-draw weapons in 2019-nCoV fight

February 4, 2020
By Anette Breindl
No Comments
At this very early point in the emerging 2019-nCoV outbreak, knowledge about the virus is insufficient to predict what shape that outbreak will ultimately take. But knowledge about the virus is accumulating at remarkable speed, and experience with other viruses is helping to shape the response to the newest coronavirus threat. 2019-nCoV, sometimes called Wuhan coronavirus after its source, is the third coronavirus after SARS-CoV and MERS-CoV with the potential to cause serious illness and death that has emerged since the beginning of the 21st century.
Read More
Coronavirus test tubes

Hong Kong researchers develop coronavirus vaccine

February 4, 2020
By David Ho and Cornelia Zou
No Comments

HONG KONG – As drug developers are racing to find a cure for the new coronavirus, researchers in Hong Kong claim to have made major headway in the development of a vaccine for the virus that has so far killed 132. Yuen Kwok-yung, the chair of infectious diseases at the University of Hong Kong’s (HKU) department of microbiology, said in a press briefing at Hong Kong’s Queen Mary Hospital that his team had successfully isolated the novel virus from the first imported case in Hong Kong. But he said the vaccine still needs months to be tested on animals and an additional year for human trials before it is fit for use.


Read More